BioXcel Closes $57.5M Teva Asset Sale, Terminates CEO and CFO, Renames Itself BX Liquidation
Summary
BioXcel completed the sale of substantially all its assets to Teva for $57.5M upfront plus up to $87.5M in milestones, terminated its CEO, CFO, CSO and CLO, and will rename itself BX Liquidation, Inc. as it winds down.
Key Events · M&A and Partnerships · BTAI
-
Teva Asset Sale Closed
On October 26, 2026, the Debtors completed the sale of substantially all neuroscience assets, including IGALMI and BXCL501, to Teva for $57.5M upfront cash, against which the $5.75M deposit was credited, plus assumed liabilities.
-
Up to $87.5M in Contingent Milestones
Teva owes up to $67.5M on FDA approval of the at-home IGALMI sNDA (declining with approval timing) and, if approval is not obtained by February 28, 2027, up to $20.0M in commercial milestones ($10M each at $250M and $500M annual net sales) through 2035.
-
Proceeds Repay DIP Lenders
At closing, sale proceeds were applied to repay the Oaktree/QIA debtor-in-possession facility, with only certain retained amounts funding the wind-down of the estates.
-
Entire Executive Team Terminated
CEO Vimal Mehta, CFO Richard Steinhart, CSO Frank Yocca and CLO Javier Rodriguez were terminated effective 5:00 p.m. ET October 31, 2026; Mehta remains a director at $5,000 per month, and Chief Restructuring Officer Samir Saleem becomes President and principal executive officer.
Analysis · BTAI · Life Sciences
The Chapter 11 sale is now complete: Teva owns IGALMI and BXCL501, and BioXcel is a shell winding down. Because the $57.5M upfront goes to repay the Oaktree/QIA DIP facility, little or nothing flows to equity; the remaining value is a contingent earnout of up to $67.5M if the FDA approves at-home IGALMI, plus up to $20M in sales milestones if approval slips past February 28, 2027. With the entire executive team terminated and the company renaming itself BX Liquidation, Inc., the operating business no longer exists. The stock is now a claim on liquidation proceeds and milestone payments, not on a drug company.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.3% of the 891 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BTAI was trading at $0.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.